Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...
The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...
In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified ...
Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...
The disease is characterized by progressive motor, cognitive, and psychiatric decline. Three treatments are approved to treat ...
The Wicked Witch of the West and I have something in common: We both use our fatal flaws to our advantage—for her, her green ...
Tapering. Spaghetti plots show that CSF NFL (right) rises more quickly in people with ADAD mutations (red) than in noncarriers (gray) and that this accelerates as disease progresses. In plasma (left), ...
Madison Elsaadi, an analyst from B.Riley Financial, reiterated the Buy rating on Wave Life Sciences (WVE – Research Report). The associated ...